Latest Conference Coverage

Ralph Kern, MD, MHSc: The State of Therapies for ALS

The chief medical officer and chief operating officer of Brainstorm Cell Therapeutics spoke about a host of topics related to the treatment of amyotrophic lateral sclerosis.

Eptinezumab Migraine Prevention Sustained in 12-Month Analysis

More than two-thirds of patients treated with intravenous infusions of the CGRP inhibitor eptinezumab had an average 50% reduction in migraines.

IncobotulinumtoxinA Successful in Treating Sialorrhea in Parkinson, Other Neurological Conditions

Study findings revealed statistically significant results at week 4 for the 100-U dose compared to placebo. The 75-U dose, while effective, did not achieve statistical significance.

Siponimod Reduces Disability Progression in Secondary Progressive Multiple Sclerosis

The data from the phase III EXPAND study indicated to the researchers that this risk reduction obtained with siponimod was substantially isolated from MS relapse.

Erenumab Displays Success in Patients Who Failed 2 or More Preventative Migraine Treatments

The calcitonin gene-related peptide inhibitor lowered monthly migraine days by ≥50% in 30.3% of patients compared to 13.7% on placebo.